At present, the potential benefits of these drugs in reducing CVD risks mainly include the reduction of multiple cardiovascular risk factors such as hyperglycemia, hypertension and hyperlipidemia, as well as other beneficial effects, including increased insulin sensitivity, weight loss, reduced of oxidative stress and low-grade inflammation, restored of endothelial function, and the inhibition of key platelet activation pathways (Standl et al., 2014; Boyle et al., 2018; Lahnwong et al., 2018; Zilov et al., 2019). This evidence concerns the gene INS and Hypertension.